Search Thermo Fisher Scientific
Disclaimer
Clicking the images or links will redirect you to a website hosted by BenchSci that provides third-party scientific content. Neither the content nor the BenchSci technology and processes for selection have been evaluated by us; we are providing them as-is and without warranty of any kind, including for use or application of the Thermo Fisher Scientific products presented.
Leinco Technologies
IL 12/23 (Briakinumab) Recombinant Human Monoclonal Antibody (ABT-874)
Product Details
LT500-1MG
Applications
Tested Dilution
Publications
Product Specifications
Species Reactivity
Human
Host/Isotype
Human
/ IgG1, lambda
Expression System
HEK293 cells
Class
Recombinant Monoclonal
Type
Antibody
Clone
ABT-874
Immunogen
This antibody was produced by phage display technology.
Conjugate
Form
Liquid
Concentration
≥5.0 mg/mL
Purification
Protein A/G
Storage buffer
PBS, pH 7.2-7.4
Contains
no preservative
Storage conditions
4°C short term, -80°C long term
Shipping conditions
Ambient (domestic); Wet ice (international)
Product Specific Information
Specificity: This non-therapeutic biosimilar antibody uses the same variable region sequence as the therapeutic antibody Briakinumab. Briakinumab recognizes both human IL12 and IL23 via IL-12/23p40. This product is for research use only.
Endotoxin Level: ≤ 1.0 EU/mg as determined by the LAL method. Purity: ≥95% monomer by analytical SEC.
Product Preparation: Functional grade preclinical antibodies are manufactured in an animal free facility using only In vitro protein free cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates. Pathogen Testing: To protect mouse colonies from infection by pathogens and to assure that experimental preclinical data is not affected by such pathogens, all of Leinco recombinant biosimilar antibodies are tested and guaranteed to be negative for all pathogens in the IDEXX IMPACT I Mouse Profile.
Storage and Handling: Functional grade biosimilar antibodies may be stored sterile as received at 2-8 C for up to one month. For longer term storage, aseptically aliquot in working volumes without diluting and store at -80 C. Avoid Repeated Freeze Thaw Cycles.
This antibody has been tested in the following applications: Western Blotting, Neutralization, Immunoprecipitation, Immunofluorescence, Functional Assay, Flow Cytometry, ELISA, Blocking.
Target Information
Briakinumab is a human anti-IL-12 monoclonal antibody being developed for the treatment of a number of T-cell driven autoimmune diseases. It targets and neutralize interleukin-12 and interleukin-23, two proteins associated with inflammation, such as pro-inflammatory interleukins or tumor necrosis factor- alpha. Briakinumab represents a novel approach to treating psoriasis, Multiple Sclerosis, Crohn's Disease and other autoimmune and inflammatory disorders. As of 2011 pharmaceutical development for psoriasis has been discontinued in the U. S. and Europe. Briakinumab targets and neutralizes interleukin-12 and interleukin-23.
For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.
References (0)
Have you cited this product in a publication?
Let us know so we can reference it here.
Performance Guarantee
If an Invitrogen™ antibody doesn't perform as described on our website or datasheet,we'll replace the product at no cost to you, or provide you with a credit for a future purchase.*
Learn more
We're here to help
Get expert recommendations for common problems or connect directly with an on staff expert for technical assistance related to applications, equipment and general product use.
Contact tech support